Business
PepGen Announces Proposed Public Offering
BOSTON, September 24, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares and pre-funded warrants are bei
About this update from Pepgen Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/67decd87afe25dd312d578ddce4a2189"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8lI35bHHjRJsKWpd7KJ9dg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/67decd87afe25dd312d578ddce4a2189","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/1ZOSrrVHkFCWI_sY088iEQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/67decd87afe25dd312d578ddce4a2189","width":1024,"height":512}},"lazy":false},{"type":"text","content":"BOSTON, September 24, 2025--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares and pre-funded warrants are being offered by PepGen. In addition, PepGen intends to grant the underwriters a 30-day option to purchase additional shares of its common stock. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.","length":858,"tagName":"p"},{"type":"text","content":"Leerink Partners and Stifel are acting as joint book-running managers for the proposed offering.","length":96,"tagName":"p"},{"type":"text","content":"PepGen currently intends to use the net proceeds from this offering to fund its ongoing research and clinical development efforts, including the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, as well as for working capital and other general corporate purposes.","length":259,"tagName":"p"},{"type":"text","content":"The securities are being offered pursuant a registration statement on Form S-3 that was previously filed with, and subsequently declared effective on July 8, 2024 by, the Securities and Exchange Commission ("SEC"). A preliminary prospec...